Baron M, et al. - The present study was performed to analyze the tolerance and efficacy of BoNT-A injection after the failure of sacral nerve modulation (SNM) for overactive bladder (iOAB). Between January 2004 and December 2017, researchers carried out a retrospective multicentric analysis of all individuals who had received either onabotulinumtoxinA or abobotulinumtoxinA intradetrusor injection for iOAB after SNM failure. A total of 76 individuals (62 females) were recruited in this study. The primary endpoint included the percentage of success of first BoNT-A injection (either resolution of their urinary incontinence or their frequency or more than 50% reduction in frequency). Results of urodynamic studies, complications, the total number of injections, causes of withdrawal, and subsequent treatment were considered as the secondary endpoints. The evidence showed that BoNT-A can be applied in SNM nonresponders with a success rate of 43.4% but is correlated with a high long-term discontinuation rate.